A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioma
- Focus Therapeutic Use
- Acronyms HERBY
- Sponsors Roche
- 07 Feb 2018 Primary endpoint (Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC)) has not been met, according to results published in the Journal of Clinical Oncology.
- 07 Feb 2018 Results (n=121) assessing bevacizumab (avastin) in combination with temozolomide (tmz) and radiotherapy in paediatric and adolescent participants with high-grade giloma, were published in the Journal of Clinical Oncology.
- 19 Dec 2017 Planned End Date changed from 31 Mar 2020 to 10 Mar 2020.